111614
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
基于网络药理学、分子对接、分子动力学模拟及体内实验探讨川芎嗪治疗创伤性脑损伤的潜在机制
Authors Tang L, Xu R, Wu Y, Cheng H
Received 12 July 2025
Accepted for publication 21 November 2025
Published 3 December 2025 Volume 2025:18 Pages 7185—7201
DOI https://doi.org/10.2147/IJGM.S553186
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Vinay Kumar
Linjun Tang,1,2,* Rong Xu,3,* Yong Wu,2 Hongwei Cheng1
1Department of Neurosurgery, the Second Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of China; 2Department of Neurosurgery, the Second People’s Hospital of Wuhu, Wuhu, People’s Republic of China; 3Department of Medical Aesthetics, the Second People’s Hospital of Wuhu, Wuhu, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Hongwei Cheng, Department of Neurosurgery, the Second Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of China, Email hongwei.cheng@ahmu.edu.cn
Background: Traumatic brain injury (TBI) is a leading cause of global disability and mortality. Tetramethylpyrazine (TMP), an active compound from Chuanxiong, holds promise for treating cerebrovascular diseases, but its precise mechanism of action against TBI remains incompletely understood. This study aimed to elucidate the therapeutic effects and underlying mechanisms of TMP in TBI.
Methods: Potential targets of TMP against TBI were identified using Swiss Target Prediction, PharmMapper, and GeneCards databases. Core targets and mechanisms were predicted through network pharmacology, molecular docking, and molecular dynamics (MD) simulations. These computational predictions were then experimentally validated in a rat TBI model, employing behavioral tests, ELISA, RT-qPCR, and Western blot analysis.
Results: Through network pharmacology analysis, 39 potential targets associated with TMP were identified. Molecular docking and MD simulations manifested that key genes like MMP3, MMP2, MMP13, and GSK3B, showed a strong binding affinity to TMP. GO analysis and KEGG analysis corroborated that such targets strongly related to the IL-17 signaling pathway and the relaxin signaling pathway. In vivo tests proved that TMP could improve the modified Neurological Severity Score (mNSS) and foot defect test scores among rats. ELISA confirmed that TMP could decrease the expression of inflammatory factors, encompassing interleukin 1 beta (IL-1β), interleukin 6 (IL-6), interleukin 17A (IL-17A), and tumor necrosis factor-alpha (TNF-α). Furthermore, RT-qPCR analysis exhibited that the levels of MMP3, MMP2, MMP13, and GSK3B were increased within the rat cortex after TBI. Significantly, TMP treatment alleviated such upregulation. Western blot analysis validated that TMP down-regulated the expression of p-GSK3β (Ser9), active MMP13, active MMP3, and P65 NF-κB proteins after TBI, while TMP increased the expression of occludin protein.
Conclusion: This study demonstrates that TMP exerts therapeutic effects on TBI by targeting the IL-17 and relaxin signalling pathways, providing evidence for its potential as a clinical therapy.
Keywords: tetramethylpyrazine, traumatic brain injury, molecular docking, molecular dynamic simulation, network pharmacology
1Department of Neurosurgery, the Second Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of China; 2Department of Neurosurgery, the Second People’s Hospital of Wuhu, Wuhu, People’s Republic of China; 3Department of Medical Aesthetics, the Second People’s Hospital of Wuhu, Wuhu, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Hongwei Cheng, Department of Neurosurgery, the Second Affiliated Hospital of Anhui Medical University, Hefei, People’s Republic of China, Email hongwei.cheng@ahmu.edu.cn
Background: Traumatic brain injury (TBI) is a leading cause of global disability and mortality. Tetramethylpyrazine (TMP), an active compound from Chuanxiong, holds promise for treating cerebrovascular diseases, but its precise mechanism of action against TBI remains incompletely understood. This study aimed to elucidate the therapeutic effects and underlying mechanisms of TMP in TBI.
Methods: Potential targets of TMP against TBI were identified using Swiss Target Prediction, PharmMapper, and GeneCards databases. Core targets and mechanisms were predicted through network pharmacology, molecular docking, and molecular dynamics (MD) simulations. These computational predictions were then experimentally validated in a rat TBI model, employing behavioral tests, ELISA, RT-qPCR, and Western blot analysis.
Results: Through network pharmacology analysis, 39 potential targets associated with TMP were identified. Molecular docking and MD simulations manifested that key genes like MMP3, MMP2, MMP13, and GSK3B, showed a strong binding affinity to TMP. GO analysis and KEGG analysis corroborated that such targets strongly related to the IL-17 signaling pathway and the relaxin signaling pathway. In vivo tests proved that TMP could improve the modified Neurological Severity Score (mNSS) and foot defect test scores among rats. ELISA confirmed that TMP could decrease the expression of inflammatory factors, encompassing interleukin 1 beta (IL-1β), interleukin 6 (IL-6), interleukin 17A (IL-17A), and tumor necrosis factor-alpha (TNF-α). Furthermore, RT-qPCR analysis exhibited that the levels of MMP3, MMP2, MMP13, and GSK3B were increased within the rat cortex after TBI. Significantly, TMP treatment alleviated such upregulation. Western blot analysis validated that TMP down-regulated the expression of p-GSK3β (Ser9), active MMP13, active MMP3, and P65 NF-κB proteins after TBI, while TMP increased the expression of occludin protein.
Conclusion: This study demonstrates that TMP exerts therapeutic effects on TBI by targeting the IL-17 and relaxin signalling pathways, providing evidence for its potential as a clinical therapy.
Keywords: tetramethylpyrazine, traumatic brain injury, molecular docking, molecular dynamic simulation, network pharmacology